Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 8114406
Peptides and their utility in modulation of behavior of cells expressing Ξ±3Ξ²1 integrins
granted -
US 8110681
Compounds for the treatment of spinal muscular atrophy and other uses
granted -
US 8110352
Method of diagnosing and treating cancer using B-catenin splice variants
granted -
US 8110354
Use of Shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo
granted -
US 8110192
Human immunodeficiency virus type 1 (HIV-1)-neutralizing human single-chain antibodies with improved breadth and potency
granted -
US 8106026
Development of a preventive vaccine for filovirus infection in primates
granted -
US 8105609
Flavivirus immunogens comprising extracellular viral particles composed of the premembrane (prM) and envelope (E) antigens
granted -
US 8105598
Human monoclonal antibodies that specifically bind IGF-II
granted -
US 8106006
Modified defensins and their use
granted -
US 8106027
Development of a preventive vaccine for filovirus infection in primates
granted -
US 8101172
Solenopsis invicta virus
granted -
US 8101380
Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs
granted -
US 8101739
Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector
granted -
US 8093343
Nitric oxide-releasing diazeniumdiolated compounds
granted -
US 8092809
Pseudomonas exotoxin A-like chimeric immunogens
granted -
US 8092988
Medium and method of deriving and using a mutated bacteria strain
granted -
US 8088787
Methods related to the treatment of neurodegenerative and inflammatory conditions
granted -
US 8088729
Anti-viral griffithsin compounds, compositions and methods of use
granted -
US 8088379
Modified T cell receptors and related materials and methods
granted -
US 8088388
Stabilized synthetic immunogen delivery system
granted -
US 8084415
Uteroglobin in the treatment of IGA mediated nephropathy
granted -
US 8084250
Defensin-antigen fusion proteins
granted -
US 8084199
Method of diagnosing poor survival prognosis colon cancer using microRNA-21
granted -
US 8084015
Stabilized synthetic immunogen delivery system
granted -
US 8084594
H2N3 influenza A viruses and methods of use
granted -
US 8080554
Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
granted -
US 8075900
Melanoma associated peptide analogues and vaccines against melanoma
granted -
US 8076100
Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
granted -
US 8075903
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3β²-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4
granted -
US 8075921
Rapamycin-resistant T cells and therapeutic uses thereof
granted -
US 8076372
Acythiols and component thiol compositions as anti-HIV and anti-retroviral agents
granted -
US 8071084
Vaccine for protection against Shigella sonnei disease
granted -
US 8071323
Human monoclonal antibodies that bind human insulin like growth factors and their use
granted -
US 8071746
Isolated nucleic acid molecule encoding a peptide or peptide analog comprising the SEQ ID No. 3
granted -
US 8071113
Live, oral vaccine for protection against Shigella dysenteriae serotype 1
granted -
US 8067563
Tumor suppressor gene, p471NG3
granted -
US 8067530
Scytovirin domain 1 related polypeptides
granted -
US 8067202
Bacterial superantigen vaccines
granted -
US 8063209
Phosphonyl ester conjugates as prodrugs
granted -
US 8063195
Mutations in a toll-like receptor motif in the NS4B of classical swine fever virus strain brescia influences virulence in swine
granted -
US 8058249
Immunostimulatory nucleic acid molecules
granted -
US 8058248
Foot and mouth disease virus vaccine comprising interferons
granted -
US 8053487
Multifunctional acrylates used as cross-linkers in dental and biomedical self-etching bonding adhesives
granted -
US 8053422
Anti-cancer oligodeoxynucleotides
granted -
US 8053443
N-substituted indenoisoquinolines and syntheses thereof
granted -
US 8048427
Subgenomic replicons of the flavivirus dengue
granted -
US 8048432
Polysaccharide-protein conjugate vaccines
granted -
US 8044185
Conformationally stabilized HIV envelope immunogens and triggering HIV-I envelope to reveal cryptic V3-loop epitopes
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory